Chromadex Corp
ChromaDex Corporation operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) t… Read more
Chromadex Corp (CDXC) - Total Assets
Latest total assets as of December 2024: $66.19 Million USD
Based on the latest financial reports, Chromadex Corp (CDXC) holds total assets worth $66.19 Million USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Chromadex Corp - Total Assets Trend (2007–2024)
This chart illustrates how Chromadex Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Chromadex Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Chromadex Corp's total assets of $66.19 Million consist of 93.9% current assets and 6.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 65.4% |
| Accounts Receivable | $7.77 Million | 11.4% |
| Inventory | $9.19 Million | 13.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $359.00K | 0.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2024)
This chart illustrates how Chromadex Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Chromadex Corp's current assets represent 93.9% of total assets in 2024, a decrease from 100.0% in 2007.
- Cash Position: Cash and equivalents constituted 65.4% of total assets in 2024, down from 100.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 84482.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 13.5% of total assets.
Chromadex Corp Competitors by Total Assets
Key competitors of Chromadex Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Chromadex Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Chromadex Corp generates 0.90x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Chromadex Corp generates $ 12.52 in net profit.
Chromadex Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.57 | 2.40 | 2.01 |
| Quick Ratio | 3.06 | 1.70 | 1.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $46.15 Million | $ 28.91 Million | $ 14.68 Million |
Chromadex Corp - Advanced Valuation Insights
This section examines the relationship between Chromadex Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.40 |
| Latest Market Cap to Assets Ratio | 5.86 |
| Asset Growth Rate (YoY) | 24.2% |
| Total Assets | $68.28 Million |
| Market Capitalization | $400.11 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Chromadex Corp's assets at a significant premium ( 5.86x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Chromadex Corp's assets grew by 24.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Chromadex Corp (2007–2024)
The table below shows the annual total assets of Chromadex Corp from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $68.28 Million | +24.22% |
| 2023-12-31 | $54.96 Million | +1.68% |
| 2022-12-31 | $54.06 Million | -6.54% |
| 2021-12-31 | $57.84 Million | +50.79% |
| 2020-12-31 | $38.36 Million | -4.69% |
| 2019-12-31 | $40.25 Million | -4.70% |
| 2018-12-31 | $42.23 Million | -32.67% |
| 2017-12-31 | $62.72 Million | +217.55% |
| 2016-12-31 | $19.75 Million | +5.35% |
| 2015-12-31 | $18.75 Million | +61.52% |
| 2014-12-31 | $11.61 Million | +29.17% |
| 2013-12-31 | $8.99 Million | -0.53% |
| 2012-12-31 | $9.03 Million | +44.09% |
| 2011-12-31 | $6.27 Million | -3.65% |
| 2010-12-31 | $6.51 Million | +82.54% |
| 2009-12-31 | $3.57 Million | -12.69% |
| 2008-12-31 | $4.08 Million | +703884.48% |
| 2007-12-31 | $580.00 | -- |